Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT06653010 | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer(Wondercel-UWD1) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06675513 | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer | Early Phase 1 | suspended | Nov 5, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | N/A | terminated | Sep 25, 2018 | University Hospital, Toulouse | recruitment difficulties | Enrollment / accrual |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking…(VEnT) | Phase 2 | terminated | Sep 27, 2024 | University of Michigan Rogel Cancer Center | Lack of Patient Interest | Other (stated, no rule matched) |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Phase 2 | terminated | Mar 8, 2021 | University of Texas Southwestern Medical Center | Sponsor decision to halt funding. | Funding |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | N/A | terminated | Apr 13, 2023 | Columbia University | Funding was withdrawn | Funding |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | — | terminated | Nov 13, 2018 | University of Washington | Study closed to accrual after meeting grant enrollment goal, prior to reaching protocol accrual… | Enrollment / accrual |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted… | N/A | suspended | May 5, 2022 | OHSU Knight Cancer Institute | Study team paused enrollment | Enrollment / accrual |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small… | Phase 1 | terminated | Apr 18, 2023 | Debiopharm International SA | The trial was concluded for strategic reasons. | Sponsor / business decision |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and…(LOOP) | — | terminated | Jan 5, 2024 | AstraZeneca | Observed event rate was below the rate required to meet study objectives. | Other (stated, no rule matched) |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African… | — | terminated | Mar 6, 2023 | Mayo Clinic | Lack of funding | Funding |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab,…(ADJUNCT) | Phase 2 | withdrawn | Aug 21, 2025 | MedSIR | The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve… | Safety / toxicity |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive… | Phase 2 | terminated | Jan 10, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | N/A | terminated | Feb 8, 2023 | RenJi Hospital | The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg,… | Safety / toxicity |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain… | N/A | terminated | Jun 13, 2024 | Roswell Park Cancer Institute | PI left | Investigator |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab… | Phase 1 | withdrawn | Dec 13, 2024 | Sichuan University | Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering… | Safety / toxicity |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With… | Phase 2 | terminated | Mar 27, 2025 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate… | Phase 1 / Phase 2 | withdrawn | Jan 9, 2026 | National Cancer Institute (NCI) | Study drug supplier withdrew support; no participants were enrolled. | Enrollment / accrual |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial… | Phase 2 | terminated | Oct 14, 2022 | University of Washington | Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the… | Enrollment / accrual |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With… | N/A | terminated | Jan 31, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | N/A | terminated | Jul 22, 2024 | Indiana University | trial stopped due to low accrual | Enrollment / accrual |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Phase 2 | terminated | Nov 2, 2021 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for… | Phase 2 | terminated | Nov 13, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young… | — | terminated | Jul 7, 2023 | Pediatric Brain Tumor Consortium | The NCI will not extend the PBTC grant beyond March 31, 2026. | Other (stated, no rule matched) |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients… | Phase 1 | terminated | Jul 9, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | Phase 1 / Phase 2 | withdrawn | Aug 28, 2025 | Centre Leon Berard | Molecule not available from the laboratory | Other (stated, no rule matched) |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung… | Phase 2 | terminated | Oct 6, 2014 | Incyte Corporation | Sponsor decision to not initiate part 2 due to slow enrollment and competing trials. | Enrollment / accrual |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously… | Phase 1 | terminated | Nov 21, 2014 | Incyte Corporation | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | Phase 1 / Phase 2 | withdrawn | Aug 5, 2016 | Eli Avisar, MD | Lack of Funding | Funding |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT05488145 | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer… | N/A | terminated | Aug 4, 2022 | Emory University | Insufficient Staff | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 8, 2026source: clinicaltrials